(VIANEWS) – Krystal Biotech (KRYS), United Community Banks (UCBI), Huron Consulting Group (HURN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Krystal Biotech (KRYS)
781.5% sales growth and 8.87% return on equity
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, Krystal Biotech has a trailing twelve months EPS of $2.18.
PE Ratio
Krystal Biotech has a trailing twelve months price to earnings ratio of 97.99. Meaning, the purchaser of the share is investing $97.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.87%.
Yearly Top and Bottom Value
Krystal Biotech’s stock is valued at $213.62 at 20:22 EST, below its 52-week high of $214.65 and way higher than its 52-week low of $93.95.
Sales Growth
Krystal Biotech’s sales growth for the next quarter is 781.5%.
2. United Community Banks (UCBI)
49.7% sales growth and 5.93% return on equity
United Community Banks, Inc. operates as a bank holding company for the United Community Bank, a state-chartered bank that provides various banking products and services. The company accepts checking, savings, money market, negotiable order of withdrawal, time, and other deposit accounts, as well as certificates of deposit. Its loan products include commercial real estate, commercial and industrial, commercial construction, residential mortgage and construction, consumer direct loans, and indirect auto loans, as well as home equity lines of credits. The company also offers investment products; wealth management services comprising financial planning, customized portfolio management, and investment advice; trust services to manage fiduciary assets; insurance products, including life insurance, long-term care insurance, and tax-deferred annuities; reinsurance on a property insurance contract; and payment processing, merchant, wire transfer, private banking, and other financial services. It serves individuals, small businesses, mid-sized commercial businesses, and non-profit organizations. The company operates through 193 locations in Georgia, North Carolina, South Carolina, Tennessee, and Florida markets. United Community Banks, Inc. was founded in 1950 and is based in Blairsville, Georgia.
Earnings Per Share
As for profitability, United Community Banks has a trailing twelve months EPS of $1.54.
PE Ratio
United Community Banks has a trailing twelve months price to earnings ratio of 20.16. Meaning, the purchaser of the share is investing $20.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.93%.
Yearly Top and Bottom Value
United Community Banks’s stock is valued at $31.05 at 20:22 EST, under its 52-week high of $31.96 and way higher than its 52-week low of $21.63.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 0.92 and the estimated forward annual dividend yield is 2.99%.
Volume
Today’s last reported volume for United Community Banks is 210579 which is 60.22% below its average volume of 529485.
3. Huron Consulting Group (HURN)
18.8% sales growth and 13.09% return on equity
Huron Consulting Group Inc., a professional services firm, provides consultancy services in the United States and internationally. It operates through three segments: Healthcare, Education, and Commercial. The Healthcare segment provides advisory services in the areas of financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; financial advisory; software products; and digital solutions, spanning technology and analytic-related services to national and regional health systems, academic and community health systems, public, children's and critical access hospitals, physician practices and medical groups, payors, and long-term care or post-acute providers. The Education segment provides research enterprise, and student and alumni lifecycle; digital solutions, spanning technology, and analytic-related services; Huron Research Suite, a software suite designed to facilitate and enhance research administration service delivery and compliance; and organizational transformation services to public and private colleges and universities, research institutes, and other education-related organizations. The Commercial segment delivers digital services and software products, and financial advisory services to financial, energy and utilities, professional and business services, life science, consumer products, and industrials and manufacturing industries, as well as public sector and nonprofit organizations. The company was incorporated in 2002 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Huron Consulting Group has a trailing twelve months EPS of $3.46.
PE Ratio
Huron Consulting Group has a trailing twelve months price to earnings ratio of 32.06. Meaning, the purchaser of the share is investing $32.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.09%.
Sales Growth
Huron Consulting Group’s sales growth is 7.9% for the current quarter and 18.8% for the next.
4. Inter Parfums (IPAR)
12.3% sales growth and 19.36% return on equity
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. It operates in two segments, European Based Operations and United States Based Operations. The company offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Moncler, Montblanc, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, Donna Karan, DKNY, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta, and Ungaro brands, as well as French Connection, Intimate, and Aziza names. It sells its products to department stores, specialty stores, duty free shops, beauty retailers, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Inter Parfums has a trailing twelve months EPS of $4.83.
PE Ratio
Inter Parfums has a trailing twelve months price to earnings ratio of 28.57. Meaning, the purchaser of the share is investing $28.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.36%.
Moving Average
Inter Parfums’s worth is way higher than its 50-day moving average of $120.10 and above its 200-day moving average of $130.40.
5. Incyte Corporation (INCY)
9.9% sales growth and 15.13% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 20.32. Meaning, the purchaser of the share is investing $20.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.13%.
6. Iron Mountain Incorporated (IRM)
9.2% sales growth and 47.37% return on equity
Iron Mountain Incorporated (NYSE: IRM), founded in 1951, is the global leader for storage and information management services. Trusted by more than 225,000 organizations around the world, and with a real estate network of more than 90 million square feet across more than 1,480 facilities in approximately 50 countries, Iron Mountain stores and protects billions of valued assets, including critical business information, highly sensitive data, and cultural and historical artifacts. Providing solutions that include secure records storage, information management, digital transformation, secure destruction, as well as data centers, cloud services and art storage and logistics, Iron Mountain helps customers lower cost and risk, comply with regulations, recover from disaster, and enable a more digital way of working.
Earnings Per Share
As for profitability, Iron Mountain Incorporated has a trailing twelve months EPS of $0.66.
PE Ratio
Iron Mountain Incorporated has a trailing twelve months price to earnings ratio of 148.91. Meaning, the purchaser of the share is investing $148.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.37%.
Yearly Top and Bottom Value
Iron Mountain Incorporated’s stock is valued at $98.28 at 20:22 EST, below its 52-week high of $100.78 and way higher than its 52-week low of $56.51.
7. Merit Medical Systems (MMSI)
8.2% sales growth and 8.45% return on equity
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Earnings Per Share
As for profitability, Merit Medical Systems has a trailing twelve months EPS of $1.74.
PE Ratio
Merit Medical Systems has a trailing twelve months price to earnings ratio of 49.15. Meaning, the purchaser of the share is investing $49.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.45%.
Yearly Top and Bottom Value
Merit Medical Systems’s stock is valued at $85.52 at 20:22 EST, below its 52-week high of $88.85 and way higher than its 52-week low of $62.58.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 7.4% and 6.7%, respectively.
Volume
Today’s last reported volume for Merit Medical Systems is 260712 which is 32.39% below its average volume of 385658.
